Skip to main content
OpenTrials
Completed

NCT Number: NCT00719693

Assessment of the Effect of Food on ABT-143 Bioavailability

Single-dose, open-label, two-period crossover study of ABT-143

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pharmacokinetic Variables

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Site Reference ID/Investigator# 9242

Evansville, Indiana, 47710, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-55 years of age (inclusive)
  • BMI 19 to 29 inclusive

Exclusion criteria

  • Asian ancestry
  • Concurrent participation in another study
  • Females pregnant or breastfeeding

Treatment and study plan

ABT-143 ( rosuvastatin calcium and fenofibric acid )

Drug

one dose under low-fat meal condition

Other names: ABT-143, fenofibric acid/rosuvastatin calcium

ABT-143 (rosuvastatin calcium and fenofibric acid )

Drug

one dose under fasting meal condition

Primary outcomes

  1. Pharmacokinetics

    Time frame: 7 days

Secondary outcomes

  1. Adverse Events

    Time frame: 30 days

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start
2008
Primary completion
2008
First posted
Jul 22, 2008
Registry last updated
Sep 28, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.